Newer studies show that antibody cocktail proposed by WHO does not treat Omicron
Recent studies on an antibody cocktail proposed by the World Health Organization (WHO) do not help patients with coronavirus infected with the micron variant. It is the cocktail of the combination of casirivimab and imdevimab antibodies.
According to Janet Diaz, WHO expert on treatment COVID-19"This antibody cocktail appears to be ineffective against microns," leading the WHO to update guidelines for cocktail use within February.
More specifically, the WHO had recommended the specific formulations for 2 categories of patients:
Those who are infected and have not yet become seriously ill, but are at high risk of going to the hospital as well as the elderly, who have previously been ill and those who have not been vaccinated. It is also recommended for use in critically ill patients with COVID-19 who have not developed antibodies against coronavirus, as reported by erntews.gr
On the other hand, according to the same WHO official, two other drugs that he has recommended since January for the treatment of patients with COVID-19 the Agency, are still effective ,. It is the active ingredient baricitinib, which was originally developed for the treatment of rheumatoid arthritis, and sotrovimab, which is a monoclonal antibody developed specifically for patients with COVID-19.